MG
BBIO icon

Michael Gelband’s BridgeBio Pharma BBIO Stock Holding History

Michael Gelband’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
+224,927
New +$15.8M 0.11% 165
2026
Q1 		– Sell
-125,302
Closed -$9.58M – 1563
2025
Q4 		$9.58M Buy
125,302
+94,874
+312% +$6.23M 0.08% 268
2025
Q3 		$1.58M Sell
30,428
-160,139
-84% -$7.81M 0.02% 807
2025
Q2 		$8.23M Buy
190,567
+155,188
+439% +$5.64M 0.07% 285
2025
Q1 		$1.22M Buy
+35,379
New +$1.19M 0.01% 866
2024
Q3 		– Sell
-14,890
Closed -$377K – 1623
2024
Q2 		$377K Buy
+14,890
New +$407K ﹤0.01% 1274
2023
Q2 		– Sell
-12,624
Closed -$209K – 1851
2023
Q1 		$209K Buy
+12,624
New +$147K ﹤0.01% 1566
2022
Q4 		– Sell
-162,981
Closed -$1.62M – 1641
2022
Q3 		$1.62M Sell
162,981
-73,131
-31% -$760K 0.02% 898
2022
Q2 		$2.14M Buy
236,112
+143,854
+156% +$1.2M 0.03% 756
2022
Q1 		$936K Buy
+92,258
New +$947K 0.01% 1201
2021
Q4 		– Sell
-26,393
Closed -$1.24M – 2167
2021
Q3 		$1.24M Buy
+26,393
New +$1.41M 0.02% 933
2021
Q2 		– Sell
-10,889
Closed -$671K – 2340
2021
Q1 		$671K Buy
+10,889
New +$712K 0.01% 1158

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Michael Gelband's BBIO Position: Q2 2026 in Review

Michael Gelband opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 224,927 shares worth $16.8M. The stake represents 0.11% of the portfolio and ranks #165 among its holdings. This is a return to the name: Michael Gelband previously reported a position in BBIO as recently as Q4 2025.

Michael Gelband first reported a position in BBIO in Q1 2021 and has held it in 12 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Michael Gelband held 224,927 shares of BridgeBio Pharma worth $16.8M as of Q2 2026.
  • BridgeBio Pharma was a new Michael Gelband position in Q2 2026.
  • BridgeBio Pharma made up 0.11% of Michael Gelband's portfolio in Q2 2026, its #165 holding.
  • Michael Gelband first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 12 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.